These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 16678548)

  • 1. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
    Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
    Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
    Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
    J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grapefruit juice enhances the exposure to oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Heiskanen T; Olkkola KT; Kalso E
    Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
    Grönlund J; Saari T; Hagelberg N; Martikainen IK; Neuvonen PJ; Olkkola KT; Laine K
    J Clin Pharmacol; 2010 Jan; 50(1):101-8. PubMed ID: 19755414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
    Chan S; Edwards SR; Wyse BD; Smith MT
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.
    Saari TI; Grönlund J; Hagelberg NM; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2010 Apr; 66(4):387-97. PubMed ID: 20076952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole drastically increases exposure to oral oxycodone.
    Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.
    Klimas R; Witticke D; El Fallah S; Mikus G
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):517-28. PubMed ID: 23488585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
    Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.
    Söderberg Löfdal KC; Andersson ML; Gustafsson LL
    Drugs; 2013 May; 73(6):533-43. PubMed ID: 23605691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
    Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
    Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
    Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
    Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers.
    Ladebo L; Foster DJR; Abuhelwa AY; Upton RN; Kongstad KT; Drewes AM; Christrup LL; Olesen AE
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):263-276. PubMed ID: 31597014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
    Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
    J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
    Lemberg KK; Heiskanen TE; Neuvonen M; Kontinen VK; Neuvonen PJ; Dahl ML; Kalso EA
    Scand J Pain; 2010 Jan; 1(1):24-33. PubMed ID: 29913934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxymorphone active uptake at the blood-brain barrier and population modeling of its pharmacokinetic-pharmacodynamic relationship.
    Sadiq MW; Boström E; Keizer R; Björkman S; Hammarlund-Udenaes M
    J Pharm Sci; 2013 Sep; 102(9):3320-31. PubMed ID: 23463542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.